Astrazeneca vs Pfizer
Astrazeneca and Pfizer are similar in size: $58.74bn and $62.58bn of revenue in their latest fiscal years. Astrazeneca grew faster (8.6% against -1.6%). Astrazeneca kept more of each dollar of sales as profit: a net margin of 17.4% against 12.4%.
| Latest fiscal year | AstrazenecaAZN, 2025 | PfizerPFE, 2025 |
|---|---|---|
| Revenue | $58.74bn | $62.58bn |
| Revenue growth | 8.6% | -1.6% |
| Net income | $10.22bn | $7.77bn |
| Operating margin | 23.4% | — |
| Net margin | 17.4% | 12.4% |
| Return on equity | 22.9% | 8.9% |
| Free cash flow | $11.77bn | $9.07bn |
| Cash | $5.71bn | $1.14bn |
| Total debt | $29.62bn | $64.80bn |
| Debt to equity | 60.9% | — |
| Dividend per share | — | $1.72 |
| Dividend yield | 1.7% | 5.5% |
| Share buybacks | $521m | — |
| Employees | — | 75,000 |
| Market value | $286.25bn | $172.19bn |
| Price vs our value range | Within our value range | Within our value range |
| Moat score | — | 78 (Strong) |
| Insider trades, 12 months | 1 buys, 1 sales | 3 buys, 2 sales |